Lexeo Therapeutics, Inc.

Ownership Transactions Reported by 19 Insiders

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, NY

Insiders trading volume in the past year

Lexeo Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Longitude Capital Partners IV, LLC 10%+ Owner $28.2M Nov 7, 2023
Omega Fund VI, L.P. 10%+ Owner $23.7M Nov 7, 2023
Lundbeckfond Invest A/S 10%+ Owner $20.2M Nov 7, 2023
Richard Nolan Townsend Chief Executive Officer, Director $2.23M -$176K -7.29% Nov 18, 2025
Eric Adler Chief Medical Officer $673K -$50.8K -7.02% Nov 18, 2025
Jenny Robertson Chief Legal Officer $634K -$49.9K -7.29% Nov 18, 2025
Tai Sandi See Chief Development Officer $607K -$47.7K -7.29% Nov 18, 2025
Jose Manuel Otero Chief Technical Officer $588K -$38.9K -6.2% Nov 18, 2025
Kyle Rasbach Chief Financial Officer $335K Jan 17, 2025
Cholmondeley Paula H Director $214K Jun 26, 2025
Louis Edward Tamayo Chief Financial Officer $212K Aug 29, 2025
Paul McCormac Chief Technical Officer $191K Nov 7, 2023
Steven Altschuler Director Jun 26, 2025
Reinaldo M. Diaz Director Jun 26, 2025
Mette Kirstine Agger Director Jun 26, 2025
Brenda Cooperstone Director Jun 26, 2025
Bernard Davitian Director Nov 2, 2023
Tolga Tanguler Director Jun 26, 2025
Timothy Van Hauwermeiren Director Jun 26, 2025

Recent Insider Transactions by Companies or Individuals for Lexeo Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.